PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Design and Discovery: Virtual Drug Screening

SBKB [doi:10.1038/sbkb.2012.180]
Technical Highlight - January 2014
Short description: Optimized crystal structure-based models yield diverse hits in a virtual screen targeting G protein-coupled receptor allosteric and orthosteric ligand-binding sites.

D3RDopa model for allosteric ligand screening, with dopamine shown in space-filling spheres. Compound #26, a new allosteric negative modulator of dopamine signaling (pIC50 = 6.31), is shown in a stick representation with yellow carbon atoms. Figure courtesy of Seva Katrich.

G protein-coupled receptors (GPCRs) are involved in numerous signaling pathways, making these transmembrane proteins potential key targets of therapeutic drugs. Recent advances in the crystallography of membrane proteins have given researchers multiple views of these notoriously difficult-to-study proteins, prompting virtual ligand screens (VLS) albeit with reportedly varied success rates. To address the utility of VLS, Katritch and colleagues (PSI GPCR Network), in collaboration with researchers from the Melbourne Institute of Pharmaceutical Sciences, Australia, screened for ligands targeting binding sites of the dopamine D3 receptor (D3R).

First, the authors performed ligand-guided receptor optimization to generate models of a D3R binding pocket in the apo (D3RAPO) and dopamine-bound (D3RDopa) states, the latter for the screening of ligands targeting a putative allosteric site. Though optimization of the D3RAPO model only slightly altered residue positions in the main orthosteric binding site (r.m.s. deviation of ∼0.9Å), validation with known D3R ligands revealed improved results.

Using these optimized models, the researchers performed VLS on a library of 4.1 million compounds. After eliminating closely related compounds and those similar to known D3R ligands, they tested the 25 top-scoring candidates for each model. Using a Ki cutoff of 10 μM in binding assays, they obtained hit rates of 56% and 32% for the D3RAPO and D3RDopa candidate sets, respectively.

In functional assays measuring the effect of candidate allosteric ligands on dopamine-induced phosphorylation of ERK1/2, two compounds had no effect, two increased phosphorylation, and the rest decreased phosphorylation to various degrees, revealing the range of functionality among identified ligands. Importantly, this approach proved its mettle with the identification of a putative novel class of D3R allosteric ligands. Thus, VLS with optimized structure-based models can be an effective complement to current drug discovery approaches as more GPCR structures become available.

Irene Kaganman

References

  1. J.R. Lane et al. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Mol. Pharmacol. 84, 794-807 (2013). doi:10.1124/mol.113.088054

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health